The collaboration of Mcule and Chemical.AI aids you in improving your synthetic capabilities

Chemical.AI, a leader for its advanced AI-driven retrosynthesis planning tools, has partnered with Mcule, an innovative online drug discovery platform. This strategic collaboration aims to integrate Mcule's extensive compound database into Chemical.AI's retrosynthesis platform.

Chemical.AI's retrosynthesis platform is used by pharmaceutical companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and biotech firms. It provides detailed synthetic routes and reaction conditions for molecules, including practical information on the availability and pricing of building blocks.

Mcule is a leading aggregator company supporting the pharmaceutical sector with compound sourcing, sample storage, and compound management services. Their database contains over 41 million purchasable small molecules from more than 250 aggregated supplier catalogs. As the pace of building block supply could significantly limit the speed of synthesis, Mcule created the Mcule Fast Building Block set, which contains over 150,000 building blocks with a maximum delivery time of two weeks.

Mcule will grant Chemical.AI access to Mcule Fast Building Block set besides their expansive database, allowing users to obtain real-time data on compound availability and pricing. This integration streamlines the planning and execution of synthetic routes, enabling researchers to identify viable synthetic pathways more efficiently and cost-effectively.

"Partnering with Mcule and integrating their extensive compound database with our retrosynthesis platform allows us to more effectively propose precise and actionable synthetic routes," said Ning Xia, CEO of Chemical.AI. "This collaboration improves our ability to serve the pharmaceutical and biotech industries by reducing the manual effort involved in synthetic route planning."

"Collaborating with Chemical.AI allows us to leverage their advanced AI and machine learning technologies to enhance the synthesis planning process," said Robert Kiss, CEO of Mcule. "We are excited to see our compounds contribute to faster and more cost-effective drug discovery and development."

Mcule.com Kft
Bartók Béla út 105-113., 1115 Budapest, Hungary
contact email: info@mcule.com

Mcule:
Mcule operates chemical marketplaces to support and speed up drug discovery pipelines and contribute to a better quality of life. We are an EU- and US-based service provider with 10+ years of experience in the compound sourcing market. We curate one of the largest in-stock compound collections and have well-established business relationships with leading academies, universities and 12 of the largest 20 pharma & biotech companies.

Chemical.AI:
Founded in 2018, Chemical.AI leads innovation in chemical synthesis through AI and automation. We work with over 100 companies and research institutes to enhance chemical synthesis strategies, processes, and productivity by integrating proprietary retrosynthesis algorithms, comprehensive chemical data, and state-of-the-art robotic lab automation. Our goal is to provide advanced cheminformatics and automated solutions across diverse sectors such as pharmaceuticals, materials, biomedicine, and chemical engineering.

This release was published on openPR.